GTHX רווח למניה בשנים עשר החודשים האחרונים G1 Pharma

The rolling 12-month EPS for G1 Therapeutics, Inc. (GTHX) reflects earnings momentum, with the metric currently standing at -0.86. A streamlined drug distribution network supports price stability. Growth is hindered by stringent FDA oversight and patent restrictions within the bone marrow protection sector. Meanwhile, research efficiency is improving through the implementation of automated cell cycle analysis systems.
G1 Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (GTHX)

A conservative investor assesses business resilience through the actual remaining earnings per share. For G1 Therapeutics, Inc. (GTHX), an innovator in bone marrow protection during chemotherapy, this criterion confirms the monetization of scientific achievements. The trend of the rolling annual earnings per share reflects net income distributed across the total volume of issuance. This metric allows for the exclusion of one-time factors to reveal the true return on equity. Stable growth of this metric guarantees a long-term margin of safety.